Mitumomab

Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.